|
NOTICESDocket No. 98E-0840, OC99123. Determination of Regulatory Review Period for Purposes of Patent Extension; Omnicef Oral Suspension. Pages 27579-27580 [FR Doc. 99-12654] [TXT] [PDF]
Docket No. 98E-0754, OC99124. Determination of Regulatory Review Period for Purposes of Patent Extension; Omnicef Tablets. Page 27578 [FR Doc. 99-12651] [TXT] [PDF]
Docket No. 98E-0474, OC99126. Determination of Regulatory Review Period for Purposes of Patent Extension; Tazorac. Pages 27578-27579 [FR Doc. 99-12652] [TXT] [PDF]
OC99134. Blood Products Advisory Committee; Notice of Meeting. Pages 27580-27581 [FR Doc. 99-12793] [TXT] [PDF]
OC99132. Circulatory Systems Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting. Page 27581 [FR Doc. 99-12792] [TXT] [PDF]
OC99119. Oncologic Drugs Advisory Committee; Notice of Meeting. Pages 27581-27582 [FR Doc. 99-12852] [TXT] [PDF]
OC99120. Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting. Page 27582 [FR Doc. 99-12653][TXT] [PDF]
Docket No. 98D-1171, CBER9814. Draft Guidance for Industry: For Platelet Testing and Evaluation of Platelet Substitute Products; Availability. Pages 27582-27583 [FR Doc. 99-12649] [TXT] [PDF] Written comments by July 19, 1999
The GuidanceDocket No. 97D-0528, CBER992. Guidance for Industry: Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use; Availability. Pages 27583-27584 [FR Doc. 99-12650][TXT] [PDF]
The Guidance